-
Mashup Score: 4Tralokinumab Found to be Efficacious, Safe for Older Adults with Moderate-to-Severe Atopic Dermatitis - 7 month(s) ago
These new results for tralokinumab could provide safer treatment options for older atopic dermatitis patients versus conventional therapies with greater risk of adverse events and drug-drug interactions.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Tralokinumab Found to be Efficacious, Safe for Older Adults with Moderate-to-Severe Atopic Dermatitis - 7 month(s) ago
These new results for tralokinumab could provide safer treatment options for older atopic dermatitis patients versus conventional therapies with greater risk of adverse events and drug-drug interactions.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Tralokinumab Found to be Efficacious in Adolescents With Moderate to Severe Atopic Dermatitis - 11 month(s) ago
Results of the phase 3 ECZTRA 6 trial found that the efficacy of the drug was maintained by more than 50% of patients at 52 weeks.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0
New results of the phase 3 ECZTRA 6 trial, evaluating tralokinumab for pediatric patients with eczema, found that the drug was superior to placebo in the primary and secondary endpoints.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0What’s New in Therapeutics With James Del Rosso, DO - 1 year(s) ago
From deucravacitinib to roflumilast to tralokinumab and everything in between, James Del Rosso, DO, previews his upcoming Winter Clinical Miami session on new therapies.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0Tralokinumab Provides Atopic Dermatitis Symptom, Severity and Quality of Life Benefit at 16 Weeks - 1 year(s) ago
New data from ECZTRA 1 and 2 show patients unable to achieve complete skin clearance nonetheless benefitted in at least 1 component of disease improvement.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
New data from ECZTRA 6 show improved sleep quality, itch relief and quality of life among teenagers treating atopic dermatitis with the IL-13 inhibitor.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
The drug is expected to be available by February 2022.
Source: www.mdedge.comCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 2Weekly Roundup: October 18-22 - 2 year(s) ago
ICYMI, some of this week’s featured content includes an exclusive interview about eczema, and articles on a new tralokinumab data, apremilast as a combination treatment, and more.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 3New Data on Investigational Tralokinumab for Treatment of AD - 2 year(s) ago
In this exclusive video interview with Dermatology Times®, Andrew Blauvelt, MD, MBA, discusses the newest phase 3 clinical data on investigational tralokinumab as a potential treatment option in atopic dermatitis.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet
A new post-hoc analysis of ECZTRA 1/2/3 found that #tralokinumab is effective & well-tolerated in patients who are 65 years or older and have moderate-to-severe #AtopicDermatitis. Check out these new findings here: https://t.co/mGjYi3kloX https://t.co/uYFPNk4MD9